Vinn - thanks for your continuous input ..always appreciated. No doubt all shareholders would share your frustration with the shenanigans going on.
On a more positive note, I think you mentioned interim analysis on CHF P3 could be the strategy and opportunity for Mesoblast towards fast track status.
Kevin DeGeeter (Ladenburg Thalmann analyst) had made the exact same point. http://www.thelifesciencesreport.com/pub/co/4251
Very happy at present(other than SP) with the recent MSB annoucements. Í'm leaving behind what's happened over the last 24 months....the Blaster is moving forward with 2 amazing Phase III's in the pipeline (not to mention the many other applications).
GLTAH.
MSB Price at posting:
$6.18 Sentiment: LT Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)